Every material Form 8-K Procter & Gamble has filed with the SEC since December 15, 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
On November 3, 2026, Procter & Gamble closed an underwritten public offering of four series of euro-denominated notes under its existing Form S-3 shelf registration, totaling €3.25 billion in principal. The notes mature between 2030 and 2046 and carry coupons from 3.750% to 4.625%, so the offering adds long-term debt to the company's balance sheet.
Four tranches: €750 million due November 3, 2030 at 3.750%; €1.0 billion due November 3, 2034 at 4.100%; €750 million due November 3, 2038 at 4.250%; €750 million due November 3, 2046 at 4.625%
Offering closed on November 3, 2026, under Registration No. 333-299472
Legal opinions filed as Exhibits 5(a) and 5(b); the filing does not state the use of proceeds
On November 2, 2026, Procter & Gamble closed an underwritten public offering of $352,231,000 in aggregate principal amount of Floating Rate Notes due November 2, 2076, sold under its existing Form S-3 registration statement. The filing is administrative, attaching legal opinions for the notes and no new financial results or guidance.
Offering closed November 2, 2026: $352,231,000 aggregate principal amount of Floating Rate Notes
Notes mature November 2, 2076, under Registration No. 333-299472
Filing attaches legal opinions (Exhibits 5(a) and 5(b)) and consents; no earnings or guidance included
Procter & Gamble closed an underwritten public offering of four series of notes totaling $4.0 billion on October 30, 2026, issued under its existing Form S-3 shelf registration. The filing discloses only the offering terms and attached legal opinions, and does not state the use of proceeds.
$750 million of 5.125% notes due October 30, 2031, and $750 million of 5.300% notes due October 30, 2033
$1.25 billion of 5.450% notes due October 30, 2036, and $1.25 billion of 5.900% notes due October 30, 2056
Issued under Registration Statement on Form S-3 (Registration No. 333-299472)
Legal opinions from Travonte Warren and Fried, Frank, Harris, Shriver & Jacobson LLP are filed as exhibits
Procter & Gamble reported first-quarter fiscal 2027 results for the period ended September 30, 2026, with organic sales up 4.0% and core EPS up 1% to $2.00. The company maintained its fiscal 2027 organic sales, core EPS and all-in EPS growth guidance and updated net sales growth guidance to +2% to +4%, while citing a $1.4 billion after-tax headwind from higher energy, transportation and raw material costs.
Organic sales grew 4.0%, with volume up 2.4%, mix up 1.1% and pricing up 0.4%.
Core EPS was $2.00, up 1%; currency-neutral core EPS was $1.99, in line with the prior year.
Core gross margin fell 150 basis points to 50.0% and core operating margin fell 80 basis points to 25.9%.
Fiscal 2027 guidance: core EPS growth of 0% to 3% and all-in EPS growth of 1% to 5%, both maintained; net sales growth of 2% to 4%, updated.
Procter & Gamble reported fiscal first-quarter 2027 net sales of $23.3 billion, up 4%, with diluted EPS of $1.97, up 1%. It raised its all-in fiscal 2027 sales growth guidance to 2% to 4% to reflect the Thorne acquisition, while keeping its organic sales, EPS and cash return guidance, but it now expects a commodity cost headwind of about $1.4 billion after tax.
Net sales of $23.3 billion, up 4%; organic sales also up 4%, with volume up 2%
Diluted EPS of $1.97, up 1%; core EPS of $2.00, up 1%
All-in fiscal 2027 sales growth guidance raised to 2% to 4%, reflecting Thorne acquisition as of October 1, 2026; organic sales guidance of 1% to 3% maintained
Fiscal 2027 diluted EPS growth guidance of 1% to 5% maintained, with a commodity cost headwind of about $1.4 billion after tax
P&G's Board declared a quarterly dividend of $1.0885 per share, payable on or after November 16, 2026, to shareholders of record on October 23, 2026. At the Annual Meeting, preliminary results show all 12 Director nominees were elected, and the company says it has increased its dividend for 70 consecutive years.
Quarterly dividend of $1.0885 per share on common and ESOP preferred stock, payable on or after November 16, 2026
Record date is October 23, 2026 for common and Series A and Series B ESOP Convertible Class A Preferred shareholders
Preliminary voting results show all 12 Director nominees elected; final results will be filed on Form 8-K
Procter & Gamble reported fiscal 2026 and fourth-quarter results on July 29, 2026, and provided fiscal 2027 guidance with slides filed as Exhibit 99.1. Full-year core EPS rose 1% to $6.89, while fourth-quarter core EPS fell 3% to $1.43, and the company guided fiscal 2027 core EPS growth of 0% to 3%, with first-quarter core EPS expected to fall 5% or more.
Fiscal 2026 organic sales grew 1% and core EPS was $6.89, up from $6.83 in the prior year on a core basis.
Fourth-quarter core EPS was $1.43 versus $1.48 a year earlier; currency-neutral core EPS fell 5% to $1.41.
Fiscal 2027 guidance: organic sales growth of 1% to 3%, core EPS growth of 0% to 3%, and all-in EPS growth of 1% to 5%.
Company guided first-quarter fiscal 2027 EPS down 5% or more and cited about $1 billion after-tax higher energy, transportation and raw material costs.
Procter & Gamble said Executive Chairman Jon Moeller will retire from the board on July 31, 2026, and from the company on August 14, 2026. President and CEO Shailesh Jejurikar will also become Chairman of the Board on August 1, 2026, while keeping his CEO role, which concentrates the top two positions in one executive.
Jon Moeller retires as Executive Chairman and director effective July 31, 2026, and leaves the company August 14, 2026
Shailesh Jejurikar, President and CEO, becomes Chairman of the Board effective August 1, 2026, in addition to his CEO role
Non-employee directors reappointed Joseph Jimenez as independent Lead Director
Procter & Gamble reported fourth-quarter and fiscal 2026 results for the quarter ended June 30, 2026. Quarterly diluted EPS fell 15% to $1.26 even as net sales rose 2%, while full-year sales and EPS grew, and the company gave fiscal 2027 growth guidance.
Q4 net sales were $21.2 billion, up 2%, with organic sales unchanged; diluted EPS was $1.26, down 15%, and core EPS was $1.43, down 3%.
Fiscal 2026 net sales were $87.0 billion, up 3%; diluted EPS was $6.62, up 2%; core EPS was $6.89, up 1%.
Fiscal 2027 guidance: all-in sales growth of 1% to 3%, diluted EPS growth of 1% to 5%, and core EPS growth in-line to 3%, or $6.89 to $7.11 per share.
P&G returned over $15 billion to shareholders in fiscal 2026, including $10.2 billion in dividends and $5.0 billion in share repurchases.
The Procter & Gamble Company declared a quarterly dividend of $1.0885 per share on its common stock and its Series A and Series B ESOP Convertible Class A Preferred Stock. Common shareowners of record at the close of business on July 24, 2026 will receive the payment, which is due on or after August 17, 2026. The release states P&G has paid a dividend for 136 consecutive years and has increased it for 70 consecutive years.
Quarterly dividend of $1.0885 per share on common and ESOP preferred stock
Common stock record date is July 24, 2026; payment on or after August 17, 2026
Company states it has increased its dividend for 70 consecutive years and paid one for 136 consecutive years
Procter & Gamble reported third-quarter fiscal 2026 results with organic sales up 3% and core earnings per share up 3% to $1.59, while currency-neutral core EPS was flat at $1.54. The company maintained its fiscal 2026 guidance, including core EPS growth of 0% to 4%, though core operating margin fell 80 basis points to 22.2%.
Organic sales grew 3%, with volume up 2% and pricing up 1%; diluted EPS was $1.63 versus $1.54 a year earlier.
Core gross margin was 50.0%, down 100 basis points, and core operating margin was 22.2%, down 80 basis points.
FY 2026 guidance was maintained: organic sales growth of 0% to 4%, core EPS growth of 0% to 4%, and all-in EPS growth of 1% to 6%.
Clorox bought P&G's minority interest in the Glad joint venture for $476 million, producing an after-tax gain of $261 million that was excluded from core EPS.
Procter & Gamble reported fiscal third-quarter 2026 results for the period ended March 31, 2026, with net sales of $21.2 billion, up 7%, and core EPS of $1.59, up 3%. Diluted EPS of $1.63 included a gain from the dissolution of the Glad joint venture, and the company now expects fiscal 2026 EPS toward the lower end of its guidance range, citing higher investment in innovation and demand creation.
Net sales $21.2 billion, up 7%; organic sales up 3%
Diluted EPS $1.63, up 6%, driven by Glad joint venture gain; core EPS $1.59, up 3%
Core operating margin down 80 basis points; fiscal 2026 EPS now expected toward lower end of guidance range
Returned $3.2 billion to shareowners, including $2.5 billion in dividends and over $600 million in buybacks
Procter & Gamble's Board declared a quarterly dividend of $1.0885 per share, which the company says is a three percent increase over the prior quarterly dividend. The dividend is payable on or after May 15, 2026, to common shareowners of record on April 24, 2026. The company says it has increased its dividend for 70 consecutive years.
Quarterly dividend of $1.0885 per share, a three percent increase over the prior quarterly dividend
Payable on or after May 15, 2026; common shareowner record date is April 24, 2026
Company says it has paid a dividend for 136 consecutive years and increased it for 70 consecutive years
Procter & Gamble reported flat organic sales and flat core earnings per share for the quarter ended December 31, 2025, while diluted EPS fell to $1.78 from $1.88 after a $0.10 restructuring charge. The company maintained its fiscal 2026 organic sales, net sales and core EPS growth guidance, which matters to shareholders because it signals no change to the full-year outlook despite soft quarterly volume.
Organic sales growth was 0%, with organic volume down 1% and pricing up 1%.
Core EPS was $1.88, flat year over year; currency-neutral core EPS was $1.85, down 2%.
Diluted EPS was $1.78 versus $1.88 a year earlier, including $0.10 of incremental restructuring.
FY 2026 guidance: organic sales growth 0% to +4%, core EPS growth 0% to +4%, and all-in EPS growth 1% to 6%.
Procter & Gamble reported fiscal second-quarter 2026 net sales of $22.2 billion, up 1%, while organic sales were unchanged and diluted EPS fell 5% to $1.78 on higher restructuring charges. The company lowered its fiscal 2026 diluted EPS growth outlook to 1% to 6% from 3% to 9%, but kept its core EPS, sales and cash return guidance, so shareholders face lower reported earnings even as underlying results held steady.
Net sales of $22.2 billion, up 1%; organic sales unchanged for the quarter ended December 31, 2025.
Diluted EPS of $1.78, down 5%; core EPS of $1.88, unchanged from the prior year.
Fiscal 2026 diluted EPS growth outlook cut to 1% to 6% from 3% to 9%; core EPS growth outlook of in-line to up 4% maintained.
Returned $4.8 billion to shareowners in the quarter: $2.5 billion in dividends and $2.3 billion in share repurchases.
Procter & Gamble's Board declared a quarterly dividend of $1.0568 per share on common and ESOP preferred stock. Common shareholders of record on January 23, 2026 will receive the payment on or after February 17, 2026. The filing notes the company has paid dividends for 135 consecutive years and increased its dividend for 69 consecutive years.
Dividend amount: $1.0568 per share on common stock and Series A and Series B ESOP Convertible Class A Preferred Stock
Record date: close of business January 23, 2026 for common stock; start of business January 23, 2026 for preferred stock
Procter & Gamble said Jennifer Davis, its Chief Executive Officer - Health Care, notified the company on December 9, 2025 of her intent to retire effective June 30, 2026, after more than 33 years of service. The filing does not name a successor or describe any change to compensation, so shareholders should note a senior leadership transition in one of the company's business units.
Jennifer Davis, Chief Executive Officer - Health Care, notified P&G of her retirement on December 9, 2025
Retirement is effective June 30, 2026
Davis has more than 33 years of service with the company
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Procter & Gamble filing is on SEC EDGAR ↗. 8-K briefs of other companies →